Medical City Plano is using advanced ECMO technology to give cardiac arrest patients a second chance at life, becoming the ...

Coredio, a digital health company developing the first software-as-a-medical-device (SaMD) platform dedicated to heart failure (HF) hemodynamic assessment, today announced that the U.S. Food and Drug ...

Secretome raises $30M Series A to advance STM-01 into Phase 2 and 3 late-stage trials for Duchenne cardiomyopathy treatment.

Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A ...

A $1-million donation to the Calgary Health Foundation will fund the renovation of a cardiac catheterization laboratory at ...

Researchers at the University Medical Center Göttingen (UMG) and the University Hospital of Schleswig-Holstein (UKSH) have made a significant breakthrough in the treatment of severe heart failure: For ...

Methodist’s mobile ECMO team is growing — new ambulances and 24/7 deployments are stretching rescue reach across the region.

Researchers at the University Medical Center Göttingen (UMG) and the University Hospital of Schleswig-Holstein (UKSH) have made a significant breakthrough in the treatment of severe heart failure: For ...

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH ...

Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

Amgen, Gilead Sciences and Regeneron Pharmaceuticals anchor big biotech with established therapies across inflammation, HIV, oncology and eye care.

Eli Lilly announced plans to acquire three early and mid-stage vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — for a combined $3.8 billion. Blackstone Life Sciences is ...